- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma, Dr Reddy's Labs recall products in US over manufacturing issues
Dr Reddy's Laboratories and Sun Pharma, two prominent pharmaceutical companies, are conducting recalls of products in the United States following revelations of manufacturing issues. This action stems from the most recent Enforcement Report published by the US Food and Drug Administration (USFDA).
Dr Reddy's Laboratories is recalling medications used to treat insomnia and gout within the American market.
According to the USFDA, New Jersey-based Dr Reddy's Laboratories, Inc., a unit of the Hyderabad-based pharmaceutical giant, has initiated a recall of 13,752 bottles of Eszopiclone tablets, USP 1mg CIV, 30-count bottle, Rx only. The affected lot was manufactured at Dr Reddy's Bachupally plant located in Telangana.
The recall was prompted by concerns over "Failed Impurities/Degradation Specifications," leading to the issuance of a Class III nationwide recall on June 4 of this year.
Class III is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences as per USFDA.
In addition to the Eszopiclone tablets, Dr Reddy's Laboratories, Inc. is also recalling 20,520 units of Allopurinol tablets, USP 300mg, 100 Tablets per bottle, Rx only from the US market due to the presence of a foreign substance. This separate recall was initiated as a Class II nationwide recall on June 7, 2024, according to the US health regulator.
Class II is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Meanwhile, Sun Pharma's US-based unit is recalling 2,088 vials of Decitabine for Injection (50mg per vial), due to "CGMP Deviations."
The affected lot of this chemotherapy medication was manufactured at Sun Pharma's plant in Gujarat. New Jersey-based Sun Pharmaceutical Industries Inc. initiated a nationwide Class II recall on July 2 of this year.
Read also: Dr Reddy's Labs, Sun Pharma recall products in American market over manufacturing issues
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751